YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
NovaBridge Biosciences ROCKVILLE, Md., Aug. 27, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) ("NovaBridge" or the "Company"), a global biotechnology company that identifies differentiated innovation and applies disciplined…
Major earnings expected before the bell on Thursday include: * Alibaba Group Holding Limited (BABA [https://seekingalpha.com/symbol/BABA]) * Walmart (WMT [https://seekingalpha.com/symbol/WMT]) * Deere & Company (DE [https://seekingalpha.co…
* NovaBridge Biosciences (NBP [https://seekingalpha.com/symbol/NBP]) appointed [https://seekingalpha.com/pr/20566287-novabridge-biosciences-appoints-dr-srishti-gupta-as-chief-executive-officer] Srishti Gupta as CEO and a member of its boar…
(RTTNews) - Biotechnology platform company NovaBridge Biosciences (NBP) announced Tuesday that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to givastomig in combination with nivolumab and chemotherapy for…
ROCKVILLE, Md., May 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unm…
(RTTNews) - NovaBridge Biosciences (NBP), a clinical-stage biotechnology firm, announced financial results for the full year ended December 31, 2025, and provided business updates for its lead investigational programs Givastomig and VIS-10…
VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitor Topline Phase 2a data show VIS-101 provides rapid, robust and durable treatment responses in wet AMD VIS-101 demon…
Appointment is a positive endorsement of NovaBridge’s unique hub-and-spoke model and focus on creating shareholder value by accelerating the development of transformative medicines for patients around the worldAs a physician-entrepreneur a…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Freedom Capital upgraded Roblox (RBLX) to…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Freedom Capital upgraded Roblox (RBLX) to…
Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined with nivolumab and chemotherapy (mFOLFOX6) in 1L HER2-negative, metastatic gastric cancer patients, with 77% ORR observed at 8 mg/kg and 73…
NovaBridge Biosciences NovaBridge Also Included in the Highly Regarded Nasdaq Biotech Index, Emphasizing its Position as an Industry Leader Opening the first trading session of the New Year marks an excellent beginning to 2026 for NovaBrid…
NovaBridge Also Included in the Highly Regarded Nasdaq Biotech Index, Emphasizing its Position as an Industry Leader Opening the first trading session of the New Year marks an excellent beginning to 2026 for NovaBridgeInclusion in the Nasd…
Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a multi-billion dollar pillar of cancer c…
(RTTNews) - NovaBridge Biosciences (NBP), a global biotechnology platform company, together with co-developer ABL Bio, reported encouraging new data from the expanded Phase 1 dosing study of Ragistomig, a 4-1BB x PD-L1 bispecific antibody.…
Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistanceThe Phase 1 ragistomig study achieved…
Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmolo…
NovaBridge subsidiary Visara assigned its exclusive license to Everest Medicines to accelerate the development of potential best-in-class therapy for wet AMD, VIS-101, leveraging Everest Medicines' strong clinical and commercialization exp…
Everest Medicines acquired an exclusive license to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and certain Southeast Asian countries. Under the assigned exclusive license, Everest Medicines wil…
NovaBridge subsidiary Visara assigned its exclusive license to Everest Medicines to accelerate the development of potential best-in-class therapy for wet AMD, VIS-101, leveraging Everest Medicines’ strong clinical and commercialization exp…